Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.152
Sell
RSI(14)
43.559
Neutral
STOCH(KDJ)(9,3,3)
35.078
Buy
ATR(14)
0.288
Low Volatility
CCI(14)
-66.536
Neutral
Williams %R
69.421
Sell
TRIX(12,20)
-0.128
Sell
StochRSI(14)
82.993
Buy
Dr Reddy's Laboratories Ltd
RDY13.770USD
-0.100-0.72%
Close 03/26, 16:00（ET）Quotes delayed by 15 min
11.46BMarket Cap
17.63P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Dr Reddy's Laboratories Ltd
Currency: USD Updated: 2026-03-25Key Insights
Dr Reddy's Laboratories Ltd's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 43 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.59.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Dr Reddy's Laboratories Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Dr Reddy's Laboratories Ltd Highlights
StrengthsRisks
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 25.74% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 3.85B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 11.81%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 11.81%.
Fairly Valued
The company’s latest PE is 17.76, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 115.20M shares, decreasing 12.19% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 361.63K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.23.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
14.585
Target Price
+6.54%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-25The current financial score of Dr Reddy's Laboratories Ltd is 8.46, ranking 60 out of 157 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 979.80M, representing a year-over-year decrease of 1.02%, while its net profit experienced a year-over-year decrease of 18.84%.
Score
Financials
6.02
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.96
Operational Efficiency
10.00
Growth Potential
8.83
Shareholder Returns
9.48
Dr Reddy's Laboratories Ltd's Company Valuation
Currency: USD Updated: 2026-03-25The current valuation score of Dr Reddy's Laboratories Ltd is 6.86, ranking 108 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 17.76, which is 18.03% below the recent high of 20.96 and 13.32% above the recent low of 15.39.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 43/157
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-25The current earnings forecast score of Dr Reddy's Laboratories Ltd is 8.00, ranking 57 out of 157 in the Pharmaceuticals industry. The average price target is 14.53, with a high of 18.82 and a low of 11.90.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
14.585
Target Price
+8.44%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
Dr Reddy's Laboratories Ltd
RDY
3
Biogen Inc
BIIB
37
Amgen Inc
AMGN
36
Eli Lilly and Co
LLY
35
Vertex Pharmaceuticals Inc
VRTX
33
Gilead Sciences Inc
GILD
32
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-25The current price momentum score of Dr Reddy's Laboratories Ltd is 7.10, ranking 48 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 14.60 and the support level at 13.27, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
13.708
Buy
MA10
13.891
Sell
MA20
14.133
Sell
MA50
13.995
Sell
MA100
13.925
Sell
MA200
14.220
Sell
Institutional Confidence
Currency: USD Updated: 2026-03-25The current institutional shareholding score of Dr Reddy's Laboratories Ltd is 3.00, ranking 93 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 13.84%, representing a quarter-over-quarter increase of 2.39%. The largest institutional shareholder is James Simons, holding a total of 8.26M shares, representing 0.99% of shares outstanding, with 10.28% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Robeco Institutional Asset Management B.V.
RBC Global Asset Management (UK) Limited
Aperio Group, LLC
Aikya Investment Management Limited
Dimensional Fund Advisors, L.P.
Parametric Portfolio Associates LLC
BNP Paribas Securities Corp. North America
State Street Investment Management (US)
1
2
Risk Assessment
Currency: USD Updated: 2026-03-25The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Dr Reddy's Laboratories Ltd is 9.40, ranking 9 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.36. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.35
VaR
+2.33%
240-Day Maximum Drawdown
+20.10%
240-Day Volatility
+21.96%
Return
Best Daily Return
60 days
+3.24%
120 days
+3.24%
5 years
+7.17%
Worst Daily Return
60 days
-2.84%
120 days
-8.15%
5 years
-12.38%
Sharpe Ratio
60 days
-0.44
120 days
-0.18
5 years
+0.07
Risk Assessment
Maximum Drawdown
240 days
+20.10%
3 years
+26.61%
5 years
+35.89%
Return-to-Drawdown Ratio
240 days
+0.41
3 years
+0.32
5 years
-0.04
Skewness
240 days
-0.65
3 years
-0.65
5 years
-0.78
Volatility
Realised Volatility
240 days
+21.96%
5 years
+22.29%
Standardised True Range
240 days
+1.79%
5 years
+1.63%
Downside Risk-Adjusted Return
120 days
-20.24%
240 days
-20.24%
Maximum Daily Upside Volatility
60 days
+19.65%
Maximum Daily Downside Volatility
60 days
+17.42%
Liquidity
Average Turnover Rate
60 days
+0.17%
120 days
+0.21%
5 years
--
Turnover Deviation
20 days
+22.71%
60 days
+69.43%
120 days
+105.87%
Peer Comparison
Pharmaceuticals
Dr Reddy's Laboratories Ltd
RDY
7.40 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.88 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.68 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ligand Pharmaceuticals Inc
LGND
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Kiniksa Pharmaceuticals International PLC
KNSA
8.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Royalty Pharma PLC
RPRX
8.41 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
